Startseite Efficiency for evaluation of disease etiologic heterogeneity in case-case and case-control studies
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Efficiency for evaluation of disease etiologic heterogeneity in case-case and case-control studies

  • Aya Kuchiba ORCID logo , Ran Gao und Molin Wang EMAIL logo
Veröffentlicht/Copyright: 30. Mai 2025
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

A disease of interest can often be classified into subtypes based on its various molecular or pathological characteristics. Recent epidemiological studies have increasingly provided evidence that some molecular subtypes in a disease may have distinct etiologies, by assessing whether the associations of a potential risk factor vary by disease subtypes (i.e., etiologic heterogeneity). Case-control and case-case studies are popular study designs in molecular epidemiology, and both can be validly applied in studies of etiologic heterogeneity. This study compared the efficiency of the etiologic heterogeneity parameter estimation between these two study designs by theoretical and numerical examinations. In settings where the two study designs have the same number of cases, the results showed that, compared with the case-case study, case-control studies always provided more efficient estimates or estimates with at least equivalent efficiency for heterogeneity parameters. In addition, we illustrated both approaches in a study for aiming to evaluate the association between plasma free estradiol and breast cancer risk according to the status of tumor estrogen and progesterone receptors, the results of which were originally provided through case-control study data.


Corresponding author: Molin Wang, Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Departments of Biostatistics and Epidemiology, Harvard T.H. Chan School of Public Health, Cambridge, MA, USA, E-mail: 

Award Identifier / Grant number: KAKENHI JP20H03950 and 21K11803

Award Identifier / Grant number: JP22ck0106551

Award Identifier / Grant number: R35 CA197735 and UM1 CA186107

Acknowledgments

We sincerely thank the reviewers and the editors for their insightful comments and constructive suggestions, which have significantly enhanced the quality of our manuscript.

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: This work was supported by the US National Institutes of Health grants R35 CA197735 and UM1CA186107, AMED JP22ck0106551 and JSPS KAKENHI JP20H03950 and 21K11803.

  7. Data availability: The data are not publicly available due to privacy or ethical restrictions. The codes are available from the corresponding author on reasonable request.

Appendix A

ARE = 1 for categorical exposure with the constrained model

Consider (K + 1)-level categorical exposure, represented by a K-dimension binary indicator X i = (Xi1, …, X iK ). Let the (K + 1)th category be the reference category. X i = (Xi1, …, X iK ) = 1 k denotes a K-dimension vector with the kth element = 1 and all other elements = 0. The components of S β 1 o = 0 include

(9) i = 1 n { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = 0 ,

and,

(10) i = 1 n { I ( Y i = 0 ) p ( Y i = 0 | U i ) } X i k = i = 1 n I ( X i = 1 k ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } , k = 1 , , K = i = 1 n k = 1 M I ( X i = 1 k ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = 0

Subtract (10) from (9), we have i = 1 n I ( X i = 0 ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = 0 , where 0 is a K-dimension zero vector.

Let a ̃ j k ( 1 ) and a ̃ j ( 0 ) denote a j i with X i = 1 k and with X i = 0, respectively. We have

i = 1 n a j i { I ( Y i = 0 ) p ( Y i = 0 | U i ) } X i k = k = 1 K a ̃ j k ( 1 ) i = 1 n I ( X i = 1 k ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = 0 .

Also,

i = 1 n a j i { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = k = 1 K a ̃ j k ( 1 ) i = 1 n I ( X i = 1 k ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } + a ̃ j ( 0 ) i = 1 n I ( X i = 0 ) { I ( Y i = 0 ) p ( Y i = 0 | U i ) } = 0 .

It follows that S α j o = S α j A .

Appendix B

ARE = 1 for α x = α w = 0

Suppose J = 2. Since α xj = α wj = 0, a2i = a21 for all i (i = 1, …, n) and thus, I α β 1 o = a 21 i = 1 n q i U i U i under the unconstrained model. From (6), it follows that Δ I = I α o a 21 I α β 1 o = 0 , that is, I α o = I α A . This proof can be straightforwardly extended to situations in which J > 2 and/or under the constrained model.

Appendix C

ARE derivation for continuous exposure and no confounder

When there is continuous exposure and no confounders, we have U i U i = 1 X i b X i X i 2 and i = 1 n q i U i U i 1 = 1 / e i = 1 n q i X i 2 i = 1 n q i X i i = 1 n q i X i i = 1 n q i , where e = i = 1 n q i X i 2 { i = 1 n q i } i = 1 n q i X i 2 . The (1,1)th element of the (d1, d2)-block of ΔI (6) is

δ d 1 d 2 11 = i = 1 n a d 1 i a d 2 i q i i = 1 n q i X i 2 i = 1 n a d 1 i q i i = 1 n a d 2 i q i i = 1 n q i X i i = 1 n a d 1 i q i X i i = 1 n a d 2 i q i i = 1 n q i X i i = 1 n a d 1 i q i X i i = 1 n a d 2 i q i + i = 1 n q i i = 1 n a d 1 i q i X i i = 1 n a d 2 i q i X i / e .

It follows that e δ d 1 d 2 11 can be written as:

e δ d 1 d 2 11 = i 1 = 1 n i 2 = 1 n i 3 = 1 n q i 1 q i 2 X i 2 2 a d 1 i 3 a d 2 i 3 q i 3 q i 1 X i 1 q i 2 X i 2 a d 1 i 3 a d 2 i 3 q i 3 q i 1 X i 1 2 q i 2 a d 1 i 2 a d 2 i 3 q i 3 + q i 1 X i 1 q i 2 a d 1 i 2 X i 2 a d 2 i 3 q i 3 + q i 1 X i 1 q i 2 a d 2 i 2 X i 2 a d 1 i 3 q i 3 q i 1 q i 2 a d 1 i 2 X i 2 a d 2 i 3 q i 3 X i 3 .

This can be simplified by rewriting the terms according to the orders of i1, i2, i3 as follows:

e δ d 1 d 2 11 = 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , d 1 s i 1 i 2 i 3 , d 2 ,

where s i 1 i 2 i 3 , d = a d i 1 ( X i 2 X i 3 ) + a d i 3 ( X i 1 X i 2 ) a d i 2 ( X i 1 X i 3 ) and t i 1 i 2 i 3 , d = a d i 1 X i 1 ( X i 2 X i 3 ) + a d i 3 X i 3 ( X i 1 X i 2 ) a d i 2 X i 2 ( X i 1 X i 3 ) . Using similar algebra for the other elements of the (d1, d2)-block matrix of ΔI, we obtain

e Δ I d 1 d 2 = 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , d 1 s i 1 i 2 i 3 , d 2 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , d 1 t i 1 i 2 i 3 , d 2 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , d 2 t i 1 i 2 i 3 , d 1 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 t i 1 i 2 i 3 , d 1 t i 1 i 2 i 3 , d 2 .

Now, assume J = 2. It follows that ΔI, I A (α) and I o (α) are all 2 × 2 matrices. This gives

e Δ I = 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 2 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 t i 1 i 2 i 3 , 1 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 t i 1 i 2 i 3 , 1 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 t i 1 i 2 i 3 , 1 2 ,

and,

I A = i = 1 n 1 a 2 i ( 1 a 2 i ) i = 1 n 1 a 2 i ( 1 a 2 i ) X i i = 1 n 1 a 2 i ( 1 a 2 i ) X i i = 1 n 1 a 2 i ( 1 a 2 i ) X i 2 .

We denote the set of {i1, i2, i3 : 1 ≤ i1 < i2 < i3n} as {m : m = 1, …, M}, q i 1 q i 2 q i 3 as Q m , s i 1 i 2 i 3 , 1 as s m , and t i 1 i 2 i 3 , 1 as t m . It follows that

I A 1 = i = 1 n 1 a 2 i ( 1 a 2 i ) X i 2 i = 1 n 1 a 2 i ( 1 a 2 i ) X i i = 1 n 1 a 2 i ( 1 a 2 i ) X i i = 1 n 1 a 2 i ( 1 a 2 i ) / ζ 1 ,

where ζ 1 = i = 1 n 1 a 2 i ( 1 a 2 i ) X i 2 { i = 1 n 1 a 2 i ( 1 a 2 i ) } i = 1 n 1 a 2 i ( 1 a 2 i ) X i 2 , and

I o 1 = I A 1 / ζ 2 + 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 t i 1 i 2 i 3 , 1 2 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 t i 1 i 2 i 3 , 1 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 t i 1 i 2 i 3 , 1 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 2 / ( e ζ 2 ) ,

where ζ2 = ζ1 + ζ3/e + ζ4/e2, ζ 3 = i = 1 n 1 a 2 i ( 1 a 2 i ) x i 2 m = 1 M Q m s m 2 + i = 1 n 1 a 2 i ( 1 a 2 i ) m = 1 M Q m t m 2 2 i = 1 n 1 a 2 i ( 1 a 2 i ) x i m = 1 M Q m s m t m , and ζ 4 = m = 1 M Q m s m 2 m = 1 M Q m t m 2 m = 1 M Q m s m t m 2 . Then,

(11) A R E = lim n 0 i = 1 n 1 a 2 i ( 1 a 2 i ) + 1 i 1 < i 2 < i 3 n q i 1 q i 2 q i 3 s i 1 i 2 i 3 , 1 2 / e ζ 1 i = 1 n 1 a 2 i ( 1 a 2 i ) ζ 2 .
Appendix D

ARE ≤ 1 for a continuous exposure and no confounder

We can rewrite ζ4 as

ζ 4 = m 1 < m 2 Q m 1 Q m 2 s m 1 2 t m 2 2 + s m 2 2 t m 1 2 2 s m 1 s m 2 t m 1 t m 2 = 1 m 1 < m 2 M Q m 1 Q m 2 { s m 1 t m 2 s m 2 t m 1 } 2 0 .

Similarly, e can be rewritten as i 1 < i 2 q i 1 q i 2 ( X i 1 X i 2 ) 2 0 . Denote the numerator and denominator of ARE in (11) as A and B, respectively. Therefore,

B A = i = 1 n 1 b 2 i ζ 3 / e + ζ 4 / e 2 m = 1 M Q m s m 2 ζ 1 / e = 1 e i = 1 n 1 b 2 i 2 m = 1 M Q m t m 2 + i = 1 n 1 b 2 i x i 2 m = 1 M Q m s m 2 2 i = 1 n 1 b 2 i x i i = 1 n 1 b 2 i m = 1 M Q m s m t m + i = 1 n 1 b 2 i ζ 4 / e 2 ,

where b2i = a2i(1 − a2i). Because ζ4 ≥ 0, we have m = 1 M Q m s m 2 m = 1 M Q m t m 2 1 / 2 m = 1 M Q m s m t m . It follows that

B A 1 e i = 1 n 1 b 2 i 2 m = 1 M Q m t m 2 + i = 1 n 1 b 2 i x i 2 m = 1 M Q m s m 2 2 i = 1 n 1 b 2 i x i i = 1 n 1 b 2 i m = 1 M Q m s m 2 m = 1 M Q m t m 2 1 / 2 + i = 1 n 1 b 2 i ζ 4 / e 2 = 1 e i = 1 n 1 b 2 i m = 1 M Q m t m 2 1 / 2 i = 1 n 1 b 2 i x i m = 1 M Q m s m 2 1 / 2 2 + i = 1 n 1 b 2 i ζ 4 / e 2 .

Note that e, ζ4, and b2i are all non-negative. Therefore BA ≥ 0, that is, ARE ≤ 1.

Appendix E

See Tables A1 and A2.

Table A1:

Bias and coverage probabilities of 95 % confidence intervals for heterogeneity parameters (αx2) of a continuous exposure X, with a continuous confounder W. n11 = n12 = 500, k = 2, exp(βw1) = 1.5, and exp(βw2) = 1.5.

Covariance between X and W βx1* αx2* Case-control study Case-case study
Bias Coverage probability Bias Coverage probability
−2 0.00 0.00 −0.001 0.940 −0.001 0.944
0.41 0.002 0.942 0.003 0.936
0.69 −0.000 0.952 −0.001 0.950
0.41 0.00 −0.002 0.962 −0.001 0.960
0.41 −0.000 0.934 0.000 0.940
0.69 0.003 0.960 0.004 0.964
0.69 0.00 0.001 0.956 0.001 0.952
0.41 0.003 0.948 0.004 0.940
0.69 0.005 0.948 0.006 0.944
−1 0.00 0.00 0.002 0.968 0.003 0.958
0.41 −0.001 0.958 0.000 0.962
0.69 0.001 0.952 0.004 0.964
0.41 0.00 0.001 0.962 0.001 0.964
0.41 0.009 0.942 0.010 0.942
0.69 −0.007 0.950 −0.008 0.946
0.69 0.00 −0.003 0.944 −0.002 0.948
0.41 0.001 0.972 0.002 0.958
0.69 0.008 0.938 0.010 0.946
1 0.00 0.00 −0.005 0.960 −0.004 0.968
0.41 −0.000 0.950 −0.001 0.964
0.69 0.002 0.950 0.004 0.938
0.41 0.00 0.002 0.950 0.002 0.952
0.41 −0.003 0.954 −0.004 0.952
0.69 0.001 0.984 0.001 0.974
0.69 0.00 0.003 0.948 0.003 0.940
0.41 0.001 0.962 0.001 0.962
0.69 0.003 0.944 0.004 0.954
2 0.00 0.00 0.003 0.958 0.004 0.954
0.41 0.007 0.940 0.008 0.954
0.69 −0.000 0.938 0.000 0.934
0.41 0.00 −0.004 0.952 −0.004 0.950
0.41 −0.002 0.950 −0.002 0.946
0.69 0.004 0.970 0.005 0.974
0.69 0.00 0.003 0.942 0.003 0.944
0.41 −0.003 0.950 −0.003 0.948
0.69 0.009 0.962 0.011 0.960
  1. *exp(0.00), exp(0.41) and exp(0.69) correspond to 1, 1.5, and 2, respectively. The data were generated using the nominal polytomous logistic regression model: p r ( Y = j | X , W ) p r ( Y = 0 | X , W ) = exp { β 01 + ( β x 1 + α x j ) X + ( β w 1 + α w j ) W } , j = 1,2 , where β01 = log(0.1/(1 − 0.1)) and αx1 = αw1 = 0. The number of controls in case-control study is kn11.

Table A2:

Bias and coverage probabilities of 95 % confidence intervals for heterogeneity parameters (αx2) of a binary X, with a binary W. n11 = n12 = 500, k = 2, exp(βw1) = 1.5, exp(βw2) = 1.5, and the prevalence of X and W in the population = 0.3.

exp(γ1) βx1* αx2* Case-control study Case-case study
Bias Coverage probability Bias Coverage probability
0.66 0.00 0.00 0.012 0.938 0.013 0.946
0.41 0.001 0.966 0.001 0.962
0.69 0.005 0.952 0.005 0.950
0.41 0.00 0.003 0.950 0.004 0.942
0.41 0.008 0.958 0.009 0.962
0.69 0.006 0.962 0.007 0.954
0.69 0.00 0.010 0.950 0.009 0.956
0.41 −0.002 0.944 −0.003 0.944
0.69 0.004 0.952 0.003 0.948
1.50 0.00 0.00 0.003 0.950 0.002 0.952
0.41 0.007 0.940 0.009 0.942
0.69 0.012 0.948 0.012 0.946
0.41 0.00 0.001 0.956 0.000 0.952
0.41 0.008 0.946 0.008 0.946
0.69 0.011 0.934 0.010 0.936
0.69 0.00 −0.006 0.938 −0.005 0.940
0.41 0.011 0.948 0.012 0.944
0.69 0.008 0.938 0.008 0.936
  1. *exp(0.00), exp(0.41) and exp(0.69) correspond to 1, 1.5, and 2, respectively. The data were generated using the nominal polytomous logistic regression model: p r ( Y = j | X , W ) p r ( Y = 0 | X , W ) = exp { β 01 + ( β x 1 + α x j ) X + ( β w 1 + α w j ) W } , j = 1,2 , where β01 = log(0.1/(1 − 0.1)) and αx1 = αw1 = 0. The number of controls in case-control study is kn11.

References

1. Campbell, PT, Jacobs, ET, Ulrich, CM, Figueiredo, JC, Poynter, JN, McLaughlin, JR, et al.. Case–control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 2010;102:391–400. https://doi.org/10.1093/jnci/djq011.Suche in Google Scholar PubMed PubMed Central

2. Leng, S, Bernauer, AM, Hong, C, Do, KC, Yingling, CM, Flores, KG, et al.. The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res 2011;17:2014–23. https://doi.org/10.1158/1078-0432.ccr-10-3026.Suche in Google Scholar PubMed PubMed Central

3. Kuchiba, A, Morikawa, T, Yamauchi, M, Imamura, Y, Liao, X, Chan, AT, et al.. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses’ health study. J Natl Cancer Inst 2012;104:415–20. https://doi.org/10.1093/jnci/djr542.Suche in Google Scholar PubMed PubMed Central

4. Holm, J, Eriksson, L, Ploner, A, Eriksson, M, Rantalainen, M, Li, J, et al.. Assessment of breast cancer risk factors reveals subtype heterogeneity. Cancer Res 2017;77:3708–17. https://doi.org/10.1158/0008-5472.can-16-2574.Suche in Google Scholar PubMed

5. Althuis, MD, Fergenbaum, JH, Garcia-Closas, M, Brinton, LA, Madigan, MP, Sherman, ME. Etiology of hormone receptor–defined breast cancer: a systematic review of the literature. Cancer Epidemiol Prev Biomarkers 2004;13:1558–68. https://doi.org/10.1158/1055-9965.1558.13.10.Suche in Google Scholar

6. Yang, XR, Chang-Claude, J, Goode, EL, Couch, FJ, Nevanlinna, H, Milne, RL, et al.. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2010;103:250–63. https://doi.org/10.1093/jnci/djq526.Suche in Google Scholar PubMed PubMed Central

7. Lee, PMY, Chan, WC, Wu, C, Tsang, KH, Law, SH, Yeung, YC, et al.. Heterogeneous associations between obesity and reproductive-related factors and specific breast cancer subtypes among Hong Kong Chinese women. Horm Cancer 2020;11:191–9. https://doi.org/10.1007/s12672-020-00386-2.Suche in Google Scholar PubMed PubMed Central

8. Chatterjee, N. A two-stage regression model for epidemiological studies with multivariate disease classification data. J Am Stat Assoc 2004;99:127–38. https://doi.org/10.1198/016214504000000124.Suche in Google Scholar

9. Wang, M, Spiegelman, D, Kuchiba, A, Lochhead, P, Kim, S, T, CA, et al.. Statistical methods for studying disease subtype heterogeneity. Stat Med 2016;35:782–800. https://doi.org/10.1002/sim.6793.Suche in Google Scholar PubMed PubMed Central

10. Zabor, EC, Begg, CB. A comparison of statistical methods for the study of etiologic heterogeneity. Stat Med 2017;36:4050–60. https://doi.org/10.1002/sim.7405.Suche in Google Scholar PubMed PubMed Central

11. Prentice, RL, Vollmer, WM, Kalbfleisch, JD. On the use of case series to identify disease risk factors. Biometrics 1984:445–58. https://doi.org/10.2307/2531397.Suche in Google Scholar

12. Begg, CB, Zhang, ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994;3:173–5.Suche in Google Scholar

13. Abubakar, M, Chang-Claude, J, Ali, HR, Chatterjee, N, Coulson, P, Daley, F, et al.. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. Int J Cancer 2018;143:746–57. https://doi.org/10.1002/ijc.31352.Suche in Google Scholar PubMed PubMed Central

14. Zhang, X, Tworoger, SS, Eliassen, AH, Hankinson, SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013;137:883–92. https://doi.org/10.1007/s10549-012-2391-z.Suche in Google Scholar PubMed PubMed Central

15. Prentice, RL, Pyke, R. Logistic disease incidence models and case-control studies. Biometrika 1979;66:403–11. https://doi.org/10.2307/2335158.Suche in Google Scholar

16. Serfling, RJ. Approximation theorems of mathematical statistics. Hoboken: John Wiley & Sons; 2009, 162.Suche in Google Scholar

17. Begg, CB. A strategy for distinguishing optimal cancer subtypes. Int J Cancer 2011;129:931–7. https://doi.org/10.1002/ijc.25714.Suche in Google Scholar PubMed PubMed Central

18. Chatterjee, N, Sinha, S, Diver, WR, Feigelson, HS. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika 2010;97:683–98. https://doi.org/10.1093/biomet/asq036.Suche in Google Scholar PubMed PubMed Central

19. Rosner, B, Glynn, RJ, Tamimi, RM, Chen, WY, Colditz, GA, Willett, WC, et al.. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 2013;178:296–308. https://doi.org/10.1093/aje/kws457.Suche in Google Scholar PubMed PubMed Central

20. Wang, M, Kuchiba, A, Ogino, S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 2015;182:263–70. https://doi.org/10.1093/aje/kwv040.Suche in Google Scholar PubMed PubMed Central

21. Li, R, Ugai, T, Xu, L, Zucker, D, Ogino, S, Wang, M. Utility of continuous disease subtyping systems for improved evaluation of etiologic heterogeneity. Cancers 2022;14. https://doi.org/10.3390/cancers14071811.Suche in Google Scholar PubMed PubMed Central

22. Begg, CB, Zabor, EC, Bernstein, JL, Bernstein, L, Press, MF, Seshan, VE. A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med 2013;32:5039–52. https://doi.org/10.1002/sim.5902.Suche in Google Scholar PubMed PubMed Central

Received: 2023-02-14
Accepted: 2025-04-20
Published Online: 2025-05-30

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 5.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ijb-2023-0027/html
Button zum nach oben scrollen